Get 40% Off
⚠ Earnings Alert! Which stocks are poised to surge?
See the stocks on our ProPicks radar. These strategies gained 19.7% year-to-date.
Unlock full list

Will Lower Revenues Dampen Finisar's (FNSR) Q2 Earnings?

Published 11/30/2018, 05:06 AM
Updated 07/09/2023, 06:31 AM

Finisar Corporation (NASDAQ:FNSR) is scheduled to report second-quarter fiscal 2019 financial results (ended Oct 28, 2018) before the opening bell on Dec 3. In the last reported quarter, the company delivered a positive earnings surprise of 50%.

Let’s find out how things are shaping up prior to the announcement.

Factors to Consider

Finisar maintains a leading position in supplying optical communications, providing components and subsystems to networking equipment manufacturers, data center operators, telecom service providers, consumer electronics and automotive companies. In its core business, the company expects to witness strong demand for ROADMs on a global basis with India and China beginning to deploy ROADMs in large volumes.

For the upcoming 5G transition for wireless, it is a leading supplier of the major OEMs of 25 gig and 100 gig data rates for both short and long-reach applications. The company is well positioned for the 100 gig to 400 gig transition in the enterprise and data center markets starting calendar year 2019.

During the second quarter of fiscal 2019, Finisar announced the sample availability of its new Flextune self-tuning feature for tunable Dense Wavelength-Division Multiplexing transceiver modules. Notably, Flextune is an automatic transceiver wavelength tuning feature that can minimize provisioning time and operating expenses.

For the second quarter, management expect revenues in the range of $315 million to $335 million primarily driven by strong demand for VCSEL arrays for 3D sensing applications in connection with the timing of product introductions, however partly offset by lower revenues associated with 10-gig and Ethernet transceivers. Furthermore, the company is making steady progress with many new VCSEL array customers for both consumer and automotive applications that will drive growth in this market segment.

For the quarter, the Zacks Consensus Estimate for total revenues stands at $328 million, down from $332 million reported in the year-earlier quarter. Adjusted earnings per share are projected at 21 cents, down from 23 cents reported a year ago.

What Our Model Says

Our proven model does not conclusively show a beat for Finisar this earnings season as it does not have the two key components. A stock needs to have both a positive Earnings ESP and a Zacks Rank #1 (Strong Buy), 2 (Buy) or 3 (Hold) for this to happen. This is not the case here as you will see below:

Earnings ESP: Finisar’s Earnings ESP, which represents the difference between the Most Accurate Estimate and the Zacks Consensus Estimate, is 0.00% as both are pegged at 21 cents. You can uncover the best stocks to buy or sell before they’re reported with our Earnings ESP Filter.

Finisar Corporation Price and EPS Surprise

Zacks Rank: Finisar currently has a Zacks Rank #3, which increases the predictive power of ESP. However, the company’s 0.00% Earnings ESP makes surprise prediction difficult.

Note that we caution against stocks with a Zacks Rank #4 or 5 (Sell-rated) going into the earnings announcement, especially when the company is seeing a negative estimate revisions momentum.

Stocks to Consider

Here are some companies that you may want to consider, as our model shows that these have the right combination of elements to post an earnings beat this quarter:

Casey's General Stores, Inc. (NASDAQ:CASY) has an Earnings ESP of +6.17% and a Zacks Rank #2. You can see the complete list of today’s Zacks #1 Rank stocks here.

Lululemon Athletica Inc. (NASDAQ:LULU) has an Earnings ESP of +1.87% and a Zacks Rank #2.

FuelCell Energy, Inc. (NASDAQ:FCEL) has an Earnings ESP of +2.94% and a Zacks Rank #2.

3 Medical Stocks to Buy Now

The greatest discovery in this century of biology is now at the flashpoint between theory and realization. Billions of dollars in research have poured into it. Companies are already generating revenue, and cures for a variety of deadly diseases are in the pipeline.

So are big potential profits for early investors. Zacks has released an updated Special Report that explains this breakthrough and names the best 3 stocks to ride it.

See them today for free >>



Finisar Corporation (FNSR): Free Stock Analysis Report

lululemon athletica inc. (LULU): Free Stock Analysis Report

Caseys General Stores, Inc. (CASY): Free Stock Analysis Report

FuelCell Energy, Inc. (FCEL): Free Stock Analysis Report

Original post

Zacks Investment Research

Latest comments

Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2024 - Fusion Media Limited. All Rights Reserved.